



Blood Products
Stem Cells
Human Tissues

Method for Expanding and Differentiating Cord Blood Cells

Application: **Cell therapy.** Facilitate transplantation in situations where a low number of hematopoietic stem cells limits clinical interventions.

Commercial interest: Cellular therapies companies.

Summary: This technology covers a new method of culturing CD34-enriched hematopoietic stem cells from cord blood that allows **increased yield in total nucleated cells, total myeloid colony-forming cells, megakaryocytic colony-forming cells and platelets.** In addition, this methodology allows to enrich the culture in megakaryocytic progenitors and fully mature megakaryocytes. Furthermore, **a more rapid megakaryocytic maturation** is obtained. Finally, platelet production in 14-day cultures is also several fold higher than standard culture methods.

Intellectual Property: This invention is protected by the following patents: US 7,452,662, CA 2,562,760, and EP 1,743,024. The European patent has been validated in France, Germany, and United Kingdom.

Owned by: Héma-Québec, Saint-Laurent, Québec, CANADA.

Information about this technology for licensing purposes can be obtained from:

Dr. Yves Blais, Ph.D., MBA

Vice-president, Research and Development

HÉMA-QUÉBEC

1070 av. des Sciences-de-la-Vie

Québec (Québec), CANADA, G1V 5C3

418 780-4362 x 3248

Email: Yves.Blais@hema-quebec.qc.ca